Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 527

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition

Open access
Kaaks, R, Rinaldi, S, Key, T J, Berrino, F, Peeters, P H M, Biessy, C, Dossus, L, Lukanova, A, Bingham, S, Khaw, K-T, Allen, N E, Bueno-de-Mesquita, H B, van Gils, C H, Grobbee, D, Boeing, H, Lahmann, P H, Nagel, G, Chang-Claude, J, Clavel-Chapelon, F, Fournier, A, Thiébaut, A, González, C A, Quirós, J R, Tormo, M-J, Ardanaz, E, Amiano, P, Krogh, V, Palli, D, Panico, S, Tumino, R, Vineis, P, Trichopoulou, A, Kalapothaki, V, Trichopoulos, D, Ferrari, P, Norat, T, Saracci, R, Riboli, E·2005·Endocrine-Related Cancer

Abstract

Considerable experimental and epidemiological evidence suggests that elevated endogenous sex steroids — notably androgens and oestrogens — promote breast tumour development. In spite of this evidence, postmenopausal androgen replacement therapy with dehydroepiandrosterone (DHEA) or testosterone has been advocated for the prevention of osteoporosis and improved sexual well-being. We have conducted a case–control study nested within the European Prospective Investigation into Cancer and Nutrition. Levels of DHEA sulphate (DHEAS), (Δ4-androstenedione), testosterone, oestrone, oestradiol and sex-hormone binding globulin (SHBG) were measured in prediagnostic serum samples of 677 postmenopausal women who subsequently developed breast cancer and 1309 matched control subjects. Levels of free testosterone and free oestradiol were calculated from absolute concentrations of testosterone, oestradiol and SHBG. Logistic regression models were used to estimate relative risks of breast cancer by quintiles of hormone concentrations. For all sex steroids –the androgens as well as the oestrogens – elevated serum levels were positively associated with breast cancer risk, while SHBG levels were inversely related to risk. For the androgens, relative risk estimates (95% confidence intervals) between the top and bottom quintiles of the exposure distribution were: DHEAS 1.69 (1.23–2.33), androstenedione 1.94 (1.40–2.69), testosterone 1.85 (1.33–2.57) and free testosterone 2.50 (1.76–3.55). For the oestrogens, relative risk estimates were: oestrone 2.07 (1.42–3.02), oestradiol 2.28 (1.61–3.23) and free oestradiol (odds ratios 2.13 (1.52–2.98)). Adjustments for body mass index or other potential confounding factors did not substantially alter any of these relative risk estimates. Our results have shown that, among postmenopausal women, not only elevated serum oestrogens but also serum androgens are associated with increased breast cancer risk. Since DHEAS and androstenedione are largely of adrenal origin in postmenopausal women, our results indicated that elevated adrenal androgen synthesis is a risk factor for breast cancer. The results from this study caution against the use of DHEA(S), or other androgens, for postmenopausal androgen replacement therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1677/erc.1.01038

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Kaaks, R., Rinaldi, S., Key, T. J., Berrino, F., Peeters, P. H. M., Biessy, C., Dossus, L., Lukanova, A., Bingham, S., Khaw, K.-T., Allen, N. E., Bueno-de-Mesquita, H. B., van Gils, C. H., Grobbee, D., Boeing, H., Lahmann, P. H., Nagel, G., Chang-Claude, J., Clavel-Chapelon, F., Fournier, A., Thiébaut, A., González, C. A., Quirós, J. R., Tormo, M.-J., Ardanaz, E., Amiano, P., Krogh, V, Palli, D., Panico, S., Tumino, R., Vineis, P., Trichopoulou, A., Kalapothaki, V, Trichopoulos, D., Ferrari, P., Norat, T., Saracci, R., & Riboli, E.
Venue
Endocrine-Related Cancer
Published
2005-12
Volume
12
Issue
4
Pages
1071-1082
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2119237938
Cited by
527
References
3
FWCI
13.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.